Skip to main content

Table 4 Adverse Events

From: Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

  Total N(%) Grade
   1 2 3–4
Apatinib alonea 45 (100%)    
Fatigue 8(17.8%) 5 2 1
Hypertension 35(77.8%) 27 3 5
Proteinuria 4(8.9%) 3 1  
Hand-foot syndrome 12(26.7%) 10 2  
Diarrhea 9(20%) 5 3 1
Weight loss 19(42.2%) 17 2  
Hair hypopigmentation 25(55.6%) 20 5  
Anorexia 17(37.8%) 10 4 3
Rash or desquamation 26(57.8%) 15 9 2
Mucositis 2(4.4%) 2   
Pneumothorax 9(20%)   3 6
Wound-healing problems 6(13.3%)   1 5
Elevated Aminotransferase or bilirubin 3(6.7%) 2 1  
Thrombocytopenia 7(15.6%) 5 1 1
Seizure-like attack 1(2.3%)    1
Pancreatitis 1(2.2%) 1   
Anemia 2(4.4%) 2   
Cranial neuritis 1(2.3%) 1   
Apatinib + everolimusb 7 (100%)    
Mucositis 7(100%) 2 4 1
Hypertension 4(57.1%) 2 2  
Rash or desquamation 5(71.4%) 2 3  
Gastrointestinal uncomfort 1(14.3%)   1  
Apatinib + GTc 5 (100%)    
Hypertension 1(20%)   1  
Rash or desquamation 2(40%) 2   
Wound-healing problems 1(20%) 1   
Thrombocytopenia 2(40%) 1 1  
  1. aApatinib alone: apatinib 500-750 mg/d according to the patient’s weight
  2. bApatinib + everolimus: apatinib 250–500 mg/d + everolimus 5 mg/d according to the patient’s weight
  3. cGT chemo-protocol combined with gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 days